Invex Therapeutics Ltd. · ASX:IXC
Invex Therapeutics — Investor Presentation (July 2019)
17 slides from Invex Therapeutics's investor presentation, Jul 5, 2019
Slide 1: Invex Therapeutics: Repurposing An Approved Drug
Invex Therapeutics Repurposing An Approved Drug Successfully raises $A12 million and lists on the Australian Stock Exchange ASX Code: IXC 5 July 2019
Slide 2: Disclaimer
Disclaimer This presentation (Presentation) is issued by Invex Therapeutics Ltd (ASX:IXC) (the Company or IXC). The information presented in this Presentation may contain predictions, estimates and other forward-looking statements. Although the company believes that its expectations are based on rea
Slide 3: Invex Therapeutics - ASX:IXC
Invex Therapeutics - ASX:IXC • Invex Therapeutics (Invex or the Company) was established March 2019 • Focused on repurposing Exenatide for neurological conditions involving raised intracranial pressure such as idiopathic intracranial hypertension(IIH) • Assignment of intellectual property from Unive
Slide 4: Capital Structure & Major Shareholders
Capital Structure & Major Shareholders Capital Structure Major Shareholders • Shares on Issue 55 mil • Directors / Management 20% • Unlisted Options* 3 mil @ 60c • Minderoo Pty Ltd 9.1% • Cash ~$A11.3 mil • Kim Hogan 7.3% • Market Cap $A 22 mil • Tony Grist 7.3% • Tom Henderson 7.3% • Jason Peterson
Slide 5: Board and Management Team
Board and Management Team • Dr Jason Loveridge, Chairman – Experienced life science investor & CEO • Prof Alexandra Sinclair, Executive Director and Chief Scientific Officer – Global scientific & clinical leader in IIH • Mr David McAuliffe, Non Executive Director – Founder of numerous life science c
Slide 6: IPO Investment Highlights
IPO Investment Highlights • Completed proof-of-concept preclinical in-vitro and in-vivo studies – data published in world leading scientific journal • Orphan Drug Designations granted for IIH in Europe (EMA) and in the US (FDA) • Phase II proof of concept clinical study initiated in IIH • Lower deve
Slide 7: Idiopathic Intracranial Hypertension (IIH)
Idiopathic Intracranial Hypertension (IIH) • Disease characterised by raised intracranial pressure & papilloedema • Symptoms – severe headaches – visual impairment, with ~25% of patients experiencing permanent loss of vision • 90% of IIH patients are obese women of childbearing age IIH peaks between
Slide 8: Ongoing Phase II Study in IIH
Ongoing Phase II Study in IIH • Phase II proof of concept single centre study • Randomised double blinded Phase II clinical study – 10 patients enrolled & completed to date 16 patients active IIH – 6 patients still to be enrolled Randomised – top-line dataset available 1H, 2020 Secondary Exenatide P
Slide 9: Rising IIH Incidence Linked to Obesity
Rising IIH Incidence Linked to Obesity • IIH is a rapidly growing orphan indication – incidence of IIH has more than doubled in the last 10 years – incidence is strongly linked to obesity in women The expanding burden of idiopathic intracranial hypertension, Susan P. Mollan, Magda Aguiar, Felicity E
Slide 10: IIH diagnosis: 5-steps, Standardised, Rapid
IIH diagnosis 5-steps, Standardised, Rapid 95% of IIH patients present at either A&E or opticians and are referred to a neurologist for diagnosis & treatment No approved drugs in IIH and a lack of an effective treatment is the real issue!! Mollan SP, et al. J Neurol Neurosurg Psychiatry 2018;0:1–13
Slide 11: IIH Treatment Guidelines
IIH Treatment Guidelines • Leading role played by Invex’s founder Prof Alexandra Sinclair • Currently no approved drugs for IIH
Slide 12: Current Therapeutic Options are Ineffective
Current Therapeutic Options are Ineffective All current medicines for IIH are unapproved*, outdated, work poorly and cause debilitating side effects Acetazolamide (1954) Most commonly used drug in IIH Cochrane review IIH in August 2015 concluded: “Insufficient evidence to recommend or reject the eff
Slide 13: Exenatide – Novel Approach to Raised ICP
Exenatide – Novel Approach to Raised ICP • Exenatide is a small peptide that binds the GLP-1 receptor • GLP-1 receptor agonists – like Exenatide - decrease fluid secretion in the kidney and are used extensively to treat diabetes • Prof Alexandra Sinclair has shown that GLP-1 receptors are also expre
Slide 14: Invex Proprietary Patented ICP Blocker
Invex Proprietary Patented* ICP Blocker • Exenatide - in its Byetta® form - was approved in 2005 for the treatment of type II diabetes in both the EU & US – administered as a twice-daily sub-cutaneous injection – commercialized by AstraZeneca – safe and well tolerated drug used in millions of diabet
Slide 15: Invex's Repurposed Pressure Blocker
Invex’s Repurposed Pressure Blocker • Proprietary and patented • Aim to be the first & only drug for IIH patients – approved for the disease (IIH) by EMA & FDA – safety and efficacy established by statistical significance in randomised, double blinded clinical trials – assigned unique National Drug
Slide 16: Repurposing Approved Drugs - An Established, Successful Business Model
Repurposing Approved Drugs - An Established, Successful Business Model Drug Original Disease New Orphan Disease Azathioprine Rheumatoid arthritis Renal transplant Bleomycin Various cancers Pleural effusion Colchicine Gout Mediterranean fever Cycloserine Urinary tract infection Tuberculosis Cyclospor
Slide 17: For more information please contact
For more information please contact
Invex Therapeutics — Investor Presentation (July 2019) on 6ix